

Chung Yin Kong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/684971/publications.pdf>

Version: 2024-02-01

109
papers

5,269
citations

117571

34
h-index

91828

69
g-index

110
all docs

110
docs citations

110
times ranked

6205
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors Influencing the False Positive Rate in CT Lung Cancer Screening. <i>Academic Radiology</i> , 2022, 29, S18-S22.	1.3	16
2	Cost-Effectiveness of Follow-Up Ultrasound for Incidental Thyroid Nodules on CT. <i>American Journal of Roentgenology</i> , 2022, 218, 615-622.	1.0	4
3	Risk of Cardiovascular Toxicity According to Tumor Laterality Among Older Patients With Early Stage Non-small Cell Lung Cancer Treated With Radiation Therapy. <i>Chest</i> , 2022, 161, 1666-1674.	0.4	2
4	Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. <i>Cancer Reports</i> , 2022, 5, e1565.	0.6	4
5	Endoscopic Screening Program for Control of Esophageal Adenocarcinoma in Varied Populations: A Comparative Cost-Effectiveness Analysis. <i>Gastroenterology</i> , 2022, 163, 163-173.	0.6	7
6	Lung cancer incidence among world trade center rescue and recovery workers. <i>Cancer Medicine</i> , 2022, 11, 3136-3144.	1.3	3
7	Impact of Comorbidities on Lung Cancer Screening Evaluation. <i>Clinical Lung Cancer</i> , 2022, 23, 402-409.	1.1	3
8	Optimizing the use of adjuvant chemotherapy in non-small cell lung cancer patients with comorbidities. <i>Current Problems in Cancer</i> , 2022, , 100867.	1.0	0
9	Assessment of treatment strategies for stage I non-small cell lung cancer in patients with comorbidities. <i>Lung Cancer</i> , 2022, 170, 34-40.	0.9	6
10	Lung cancer treatment patterns in patients with diabetes.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18723-e18723.	0.8	0
11	Optimal treatment strategies for stage I non-small cell lung cancer in veterans with pulmonary and cardiac comorbidities. <i>PLoS ONE</i> , 2021, 16, e0248067.	1.1	6
12	Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 988.	3.8	181
13	Cost-Effectiveness of Management Algorithms for Lung-RADS Category 4 Nodules. <i>Radiology: Cardiothoracic Imaging</i> , 2021, 3, e200523.	0.9	2
14	Cost-effectiveness analysis of platinum-based chemotherapy treatment options for germline BRCA-mutated locally advanced/borderline resectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16246-e16246.	0.8	0
15	Cost-Effectiveness of Treatment Thresholds for Subsolid Pulmonary Nodules in CT Lung Cancer Screening. <i>Radiology</i> , 2021, 300, 586-593.	3.6	9
16	Cost-Effectiveness of Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Simulation Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1065-1073.	3.0	34
17	Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. <i>JAMA Oncology</i> , 2021, 7, 1833.	3.4	29
18	A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies. <i>Journal of the National Cancer Institute</i> , 2020, 112, 466-479.	3.0	67

#	ARTICLE	IF	CITATIONS
19	Optimizing Management of Patients With Barrett's Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1961-1969.	2.4	15
20	Cost-Effectiveness Analysis of Lung Cancer Screening in the United States. <i>Annals of Internal Medicine</i> , 2020, 172, 706-707.	2.0	2
21	The Effect of Advances in Lung-Cancer Treatment on Population Mortality. <i>New England Journal of Medicine</i> , 2020, 383, 640-649.	13.9	893
22	Performance of Lung Nodule Management Algorithms for Lung-RADS Category 4 Lesions. <i>Academic Radiology</i> , 2020, 28, 1037-1042.	1.3	9
23	Effect and cost-effectiveness of national gastric cancer screening in Japan: a microsimulation modeling study. <i>BMC Medicine</i> , 2020, 18, 257.	2.3	37
24	Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US. <i>JAMA Network Open</i> , 2020, 3, e2016144.	2.8	24
25	Cost and Utilization of Lung Cancer End-of-Life Care Among Racial-Ethnic Minority Groups in the United States. <i>Oncologist</i> , 2020, 25, e120-e129.	1.9	20
26	Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden. <i>PLoS ONE</i> , 2020, 15, e0228288.	1.1	12
27	Cost-Effectiveness of Follow-Up for Subsolid Pulmonary Nodules in High-Risk Patients. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1298-1305.	0.5	9
28	Racial/ethnic disparities in colorectal cancer treatment utilization and phase-specific costs, 2000-2014. <i>PLoS ONE</i> , 2020, 15, e0231599.	1.1	38
29	Esophageal cancer treatment costs by phase of care and treatment modality, 2000-2013. <i>Cancer Medicine</i> , 2019, 8, 5158-5172.	1.3	21
30	A simulation study of the effect of lung cancer screening in China, Japan, Singapore, and South Korea. <i>PLoS ONE</i> , 2019, 14, e0220610.	1.1	5
31	Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States. <i>JAMA Network Open</i> , 2019, 2, e1911952.	2.8	47
32	Cancer Risk in Subsolid Nodules in the National Lung Screening Trial. <i>Radiology</i> , 2019, 293, 441-448.	3.6	47
33	The effect of radiographic emphysema in assessing lung cancer risk. <i>Thorax</i> , 2019, 74, 858-864.	2.7	24
34	Development and validation of a model to predict outcomes of colon cancer surveillance. <i>Cancer Causes and Control</i> , 2019, 30, 767-778.	0.8	3
35	Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer. <i>In Reply. JAMA Oncology</i> , 2019, 5, 1066.	3.4	1
36	Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. <i>PLoS ONE</i> , 2019, 14, e0215409.	1.1	7

#	ARTICLE	IF	CITATIONS
37	Disparities and Trends in Genetic Testing and Erlotinib Treatment among Metastatic Non-Small Cell Lung Cancer Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 926-934.	1.1	27
38	Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results. <i>JAMA Network Open</i> , 2019, 2, e190204.	2.8	70
39	Cost-Effectiveness Analysis of Lung Cancer Screening in the United States. <i>Annals of Internal Medicine</i> , 2019, 171, 796.	2.0	81
40	Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013. <i>Medicine (United States)</i> , 2019, 98, e18082.	0.4	13
41	Short-term outcomes for lung cancer resection surgery in HIV infection. <i>Aids</i> , 2019, 33, 1353-1360.	1.0	9
42	Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare. <i>Cancer Medicine</i> , 2019, 8, 94-103.	1.3	54
43	Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 180.e11-180.e18.	0.8	12
44	Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. <i>Oncologist</i> , 2019, 24, 945-954.	1.9	13
45	A Decision Analysis of Follow-up and Treatment Algorithms for Nonsolid Pulmonary Nodules. <i>Radiology</i> , 2019, 290, 506-513.	3.6	17
46	Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach. <i>American Journal of Roentgenology</i> , 2019, 212, 596-601.	1.0	4
47	Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. <i>JAMA Oncology</i> , 2019, 5, 358.	3.4	48
48	Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. <i>Cancer Medicine</i> , 2018, 7, 525-535.	1.3	136
49	Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 392-400.e7.	2.4	17
50	Re: Think before you leap. <i>International Journal of Cancer</i> , 2018, 142, 1507-1509.	2.3	0
51	Patterns and predictors of end-of-life care in older patients with pancreatic cancer. <i>Cancer Medicine</i> , 2018, 7, 6401-6410.	1.3	20
52	Analysis of factors associated with extended recovery time after colonoscopy. <i>PLoS ONE</i> , 2018, 13, e0199246.	1.1	4
53	Smoking and Lung Cancer Mortality in the United States From 2015 to 2065. <i>Annals of Internal Medicine</i> , 2018, 169, 684.	2.0	150
54	Hospice use and end-of-life care among older patients with esophageal cancer. <i>Health Science Reports</i> , 2018, 1, e76.	0.6	16

#	ARTICLE	IF	CITATIONS
55	Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model. <i>Pancreatology</i> , 2018, 18, 928-934.	0.5	32
56	Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/ μ l. <i>Aids</i> , 2018, 32, 1333-1342.	1.0	35
57	Survival Disparities by Race and Ethnicity in Early Esophageal Cancer. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2880-2888.	1.1	18
58	Cost-effectiveness of immune checkpoint inhibition in metastatic gastric and esophageal tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 56-56.	0.8	1
59	Population impact of lung cancer screening in the United States: Projections from a microsimulation model. <i>PLoS Medicine</i> , 2018, 15, e1002506.	3.9	21
60	Cost-effectiveness of single versus dual immune checkpoint blockade for chemotherapy-refractory esophageal, GE junction, and gastric cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16089-e16089.	0.8	0
61	Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1471-1474.	2.4	20
62	The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. <i>International Journal of Cancer</i> , 2017, 140, 2436-2443.	2.3	36
63	Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1397-1404.e7.	2.4	51
64	The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival. <i>American Journal of Gastroenterology</i> , 2017, 112, 1256-1264.	0.2	45
65	Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. <i>JAMA Internal Medicine</i> , 2017, 177, 1613.	2.6	99
66	Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. <i>PLoS Medicine</i> , 2017, 14, e1002277.	3.9	216
67	The thyroid cancer policy model: A mathematical simulation model of papillary thyroid carcinoma in The U.S. population. <i>PLoS ONE</i> , 2017, 12, e0177068.	1.1	5
68	Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach. <i>PLoS ONE</i> , 2017, 12, e0173119.	1.1	9
69	Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: Results of a decision analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4117-4117.	0.8	0
70	Disparities in cancer outcomes across age, sex, and race/ethnicity among pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18071-e18071.	0.8	0
71	Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size. <i>Pancreas</i> , 2016, 45, 1062-1066.	0.5	33
72	Evaluating the impacts of screening and smoking cessation programmes on lung cancer in a high-burden region of the USA: a simulation modelling study. <i>BMJ Open</i> , 2016, 6, e010227.	0.8	16

#	ARTICLE	IF	CITATIONS
73	Combined Biomarker and Computed Tomography Screening Strategies for Lung Cancer. <i>MDM Policy and Practice</i> , 2016, 1, 238146831664396.	0.5	4
74	Screening for Pancreatic Adenocarcinoma in BRCA2 Mutation Carriers: Results of a Disease Simulation Model. <i>EBioMedicine</i> , 2015, 2, 1980-1986.	2.7	14
75	Identifying Best-Fitting Inputs in Health-Economic Model Calibration. <i>Medical Decision Making</i> , 2015, 35, 170-182.	1.2	17
76	High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis. <i>World Journal of Gastroenterology</i> , 2015, 21, 5513.	1.4	13
77	Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: A decision analysis. <i>Cancer</i> , 2015, 121, 1556-1562.	2.0	23
78	Comparing Morbidities of Testing With a New Index: Screening Colonoscopy Versus Core-Needle Breast Biopsy. <i>Journal of the American College of Radiology</i> , 2015, 12, 295-301.	0.9	12
79	Targeted Screening of Individuals at High Risk for Pancreatic Cancer: Results of a Simulation Model. <i>Radiology</i> , 2015, 275, 177-187.	3.6	34
80	Comparing Benefits from Many Possible Computed Tomography Lung Cancer Screening Programs: Extrapolating from the National Lung Screening Trial Using Comparative Modeling. <i>PLoS ONE</i> , 2014, 9, e99978.	1.1	38
81	Statins and Aspirin for Chemoprevention in Barrett's Esophagus: Results of a Cost-Effectiveness Analysis. <i>Cancer Prevention Research</i> , 2014, 7, 341-350.	0.7	27
82	Imaging for Appendicitis: Should Radiation-induced Cancer Risks Affect Modality Selection?. <i>Radiology</i> , 2014, 273, 472-482.	3.6	10
83	Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. <i>Cancer</i> , 2014, 120, 1713-1724.	2.0	65
84	Exploring the Recent Trend in Esophageal Adenocarcinoma Incidence and Mortality Using Comparative Simulation Modeling. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 997-1006.	1.1	61
85	A simulation model of colorectal cancer surveillance and recurrence. <i>BMC Medical Informatics and Decision Making</i> , 2014, 14, 29.	1.5	12
86	Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2014, 160, 311.	2.0	377
87	JOURNAL CLUB: How Radiation Exposure Histories Influence Physician Imaging Decisions: A Multicenter Radiologist Survey Study. <i>American Journal of Roentgenology</i> , 2013, 200, 1275-1283.	1.0	23
88	Microsimulation Model Predicts Survival Benefit of Radiofrequency Ablation and Stereotactic Body Radiotherapy Versus Radiotherapy for Treating Inoperable Stage I Non-small Cell Lung Cancer. <i>American Journal of Roentgenology</i> , 2013, 200, 1020-1027.	1.0	11
89	Patients with Testicular Cancer Undergoing CT Surveillance Demonstrate a Pitfall of Radiation-induced Cancer Risk Estimates: The Timing Paradox. <i>Radiology</i> , 2013, 266, 896-904.	3.6	35
90	Patient and Societal Value Functions for the Testing Morbidities Index. <i>Medical Decision Making</i> , 2013, 33, 819-838.	1.2	16

#	ARTICLE	IF	CITATIONS
91	Trends in esophageal adenocarcinoma incidence and mortality. <i>Cancer</i> , 2013, 119, 1149-1158.	2.0	439
92	Impact of Reduced Tobacco Smoking on Lung Cancer Mortality in the United States During 1975-2000. <i>Journal of the National Cancer Institute</i> , 2012, 104, 541-548.	3.0	145
93	Using Radiation Risk Models in Cancer Screening Simulations: Important Assumptions and Effects on Outcome Projections. <i>Radiology</i> , 2012, 262, 977-984.	3.6	30
94	Chapter 9: The MGH-HMS Lung Cancer Policy Model: Tobacco Control Versus Screening. <i>Risk Analysis</i> , 2012, 32, S117-24.	1.5	37
95	Aspirin Protects Against Barrett's Esophagus in a Multivariate Logistic Regression Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 722-727.	2.4	57
96	The Cost Effectiveness of Radiofrequency Ablation for Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 143, 567-575.	0.6	143
97	Quality-of-Life Assessment of Fibroid Treatment Options and Outcomes. <i>Radiology</i> , 2011, 259, 785-792.	3.6	32
98	The Impact of Obesity on the Rise in Esophageal Adenocarcinoma Incidence: Estimates from a Disease Simulation Model. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2450-2456.	1.1	38
99	Cost-Effectiveness of Computed Tomography Screening for Lung Cancer in the United States. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1841-1848.	0.5	213
100	Initial development of the Temporary Utilities Index: a multiattribute system for classifying the functional health impact of diagnostic testing. <i>Quality of Life Research</i> , 2010, 19, 401-412.	1.5	13
101	Development, Calibration, and Validation of a U.S. White Male Population-Based Simulation Model of Esophageal Adenocarcinoma. <i>PLoS ONE</i> , 2010, 5, e9483.	1.1	15
102	Projected Costs, Risks, and Benefits of Expanded Newborn Screening for MCADD. <i>Pediatrics</i> , 2010, 125, e286-e294.	1.0	34
103	Convergent Evolution of Novel Protein Function in Shrew and Lizard Venom. <i>Current Biology</i> , 2009, 19, 1925-1931.	1.8	53
104	Calibration of Disease Simulation Model Using an Engineering Approach. <i>Value in Health</i> , 2009, 12, 521-529.	0.1	53
105	Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines. <i>Pharmacoeconomics</i> , 2009, 27, 533-545.	1.7	99
106	Adopting helical CT screening for lung cancer. <i>Cancer</i> , 2008, 113, 3440-3449.	2.0	29
107	Estimating Long-term Effectiveness of Lung Cancer Screening in the Mayo CT Screening Study. <i>Radiology</i> , 2008, 248, 278-287.	3.6	94
108	Simulations of Stochastic Sensing of Proteins. <i>Journal of the American Chemical Society</i> , 2005, 127, 18252-18261.	6.6	37

#	ARTICLE	IF	CITATIONS
109	Tissue scale agent-based simulation of premalignant progressions in Barrett's esophagus. Simulation, 0, , 003754972110400.	1.1	1